January 15, 2026Be sure to catch up on the latest happenings in our winter newsletter here!- January 6, 2026Each year, landmarks, homes, and communities across the country light up in red to honor those affected by amyloidosis and…
November 12, 2025JAMA Cardiol Published Online: November 8, 2025 Today at the AHA congress in New Orleans, BridgeBio presented data showing that acoramidis significantly reduces…- May 21, 2025Be sure to catch up on the latest happenings in our fall newsletter here!
- May 21, 2025Alnylam and BridgeBio are competing for people who are switching from Pfizer’s blockbuster ATTR amyloidosis drug tafamidis while all three…
- May 21, 2025Below is a resource for our patients: Taylor & Francis is a publisher of peer-reviewed medical journals. We publish a…
- May 14, 2025- ATTRibute-CM, BridgeBio’s Phase 3 clinical trial of acoramidis in patients with ATTR-CM, achieved statistical significance in reducing the risk…
- April 3, 2025PALO ALTO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new…
- March 26, 2025CAMBRIDGE, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on…
- March 21, 2025− Novel Mechanism of Action Delivers Rapid Knockdown of Transthyretin, Addressing the Disease at its Source – − Proven Consistency…
7151 N. Main St. Ste. 2 Clarkston, MI 48346
248-922-9610